David Ricks, Eli Lilly CEO (Al Drago/Bloomberg via Getty Images)
October 3, 2023 07:24 AM EDTUpdated 10:00 AM
Deals
Pharma

Eli Lil­ly to buy ra­dio­phar­ma com­pa­ny Point Bio­phar­ma for $1.4B as PhI­II read­out looms

Kyle LaHucik

Senior Reporter

On a deal­mak­ing spree, Eli Lil­ly will buy an­oth­er can­cer biotech, this time swoop­ing in for pub­licly trad­ed ra­dio­phar­ma com­pa­ny Point Bio­phar­ma in a cash …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times